genome editing for thalassemia caf patient-family conference 21 june 2014 daniel e. bauer, md phd
DESCRIPTION
Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD. Disclosures. • Consultant for Editas Medicine. Genetics: each cell carries a genome. ASHG.org. The genome is composed of DNA, 3 billion positions. education-portal.com. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/1.jpg)
Genome Editing for Thalassemia
CAF Patient-Family Conference21 June 2014
Daniel E. Bauer, MD PhD
![Page 2: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/2.jpg)
Disclosures
• Consultant for Editas Medicine
![Page 3: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/3.jpg)
Genetics: each cell carries a genome
ASHG.org
![Page 4: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/4.jpg)
The genome is composed of DNA, 3 billion positions
education-portal.com
![Page 5: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/5.jpg)
The genome includes lots of DNA …
education-portal.com
![Page 6: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/6.jpg)
… with many genes …
![Page 7: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/7.jpg)
… and even more non-coding DNA.
education-portal.com
![Page 8: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/8.jpg)
Genome editing
![Page 9: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/9.jpg)
Genome editing
![Page 10: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/10.jpg)
Genome editing tools are sequence-specific nucleases
van der Oost. Science (2013) 339:768.
Genome editing tools have two features:
1)Recognize specific DNA sequences (i.e. specific genes or non-coding elements)
![Page 11: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/11.jpg)
Genome editing tools are sequence-specific nucleases
van der Oost. Science (2013) 339:768.
Genome editing tools have two features:
1)Recognize specific DNA sequences (i.e. specific genes or non-coding elements)
![Page 12: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/12.jpg)
Genome editing tools are sequence-specific nucleases
van der Oost. Science (2013) 339:768.
Genome editing tools have two features:
1)Recognize specific DNA sequences (i.e. specific genes or non-coding elements)
![Page 13: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/13.jpg)
Genome editing tools are sequence-specific nucleases
van der Oost. Science (2013) 339:768.
Genome editing tools have two features:
1)Recognize specific DNA sequences (i.e. specific genes or non-coding elements)
2)Cut DNA (“nuclease”), then a scar is left behind
![Page 14: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/14.jpg)
Genome editing: cleavage repair can either disrupt original sequence or replace it with a new copy
NEB.com
![Page 15: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/15.jpg)
Genome editing: cleavage repair can either disrupt original sequence or replace it with a new copy
NEB.com
“delete”
![Page 16: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/16.jpg)
Genome editing: cleavage repair can either disrupt original sequence or replace it with a new copy
NEB.com
“delete” “copy and paste”
![Page 17: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/17.jpg)
Two strategies for genetic therapy: gene addition and genome editing
Fischer. Nature (2014) 510:226.
![Page 18: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/18.jpg)
Two strategies for genetic therapy: addition and editing
• Gene addition:• Feasible with existing technology; clinical trials ongoing.• Early trial results appear exciting.• Challenges:
1. Will enough of the added gene be made in the cells with the integration? Will enough of the blood stem cells have the added gene?2. Is the benefit durable? Will the added gene continue to function over days, weeks, months, years, decades?3. Is the added gene safe? Will its semi-random integration into the genome change the function of other genes in the genome?
Fischer. Nature (2014) 510:226.
![Page 19: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/19.jpg)
Two strategies for genetic therapy: addition and editing
• Gene editing:• Promise of permanent repair of the underlying disease-causing mutation.• Promise of specific beneficial change at the intended genomic site (e.g.-
globin gene) without impacting remainder of genome.• Challenges:
1. Technology is in a relatively early stage and needs to be further developed.2. Can enough cells be edited to have therapeutic impact?3. Will the editing be exquisitely specific, or will other regions of the genome aside from the target be affected?
Fischer. Nature (2014) 510:226.
![Page 20: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/20.jpg)
Thalassemia is caused by mutations of the or -globin genes
![Page 21: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/21.jpg)
Many different mutations of the -globin gene cause -thalassemia
![Page 22: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/22.jpg)
The problem in -thalassemia is too much -globinrelative to -globin
![Page 23: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/23.jpg)
-globin (fetal hemoglobin) can functionally substitutefor -globin (adult hemoglobin)
![Page 24: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/24.jpg)
BCL11A enhancer determines fetal hemoglobin level
Hardison and Blobel. Science (2013) 342:206.
![Page 25: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/25.jpg)
BCL11A enhancer determines fetal hemoglobin level
Hardison and Blobel. Science (2013) 342:206.
![Page 26: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/26.jpg)
BCL11A enhancer determines fetal hemoglobin level
Hardison and Blobel. Science (2013) 342:206.
![Page 27: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/27.jpg)
• Collect blood stem cells from patient with -thalassemia
• Introduce sequence-specific nucleases to disrupt BCL11A enhancer
• Reinfuse modified blood stem cells to patient
The vision: mimicking common protective genetic variation for therapeutic benefit
![Page 28: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/28.jpg)
• Collect blood stem cells from patient with -thalassemia
• Introduce sequence-specific nucleases to disrupt BCL11A enhancer
• Reinfuse modified blood stem cells to patient
Potential benefits:
• Loss of BCL11A expression in red blood cells causing increased fetal hemoglobin
• Spares BCL11A expression in other blood cells
• Modification would be permanent
• Survival advantage of cells (would outcompete unmodified cells)
• Compared to gene addition, no semi-random insertion of material into the genome, and no need for lifelong expression of foreign sequences
The vision: mimicking common protective genetic variation for therapeutic benefit
![Page 29: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/29.jpg)
• Collect blood stem cells from patient with -thalassemia
• Introduce sequence-specific nucleases to disrupt BCL11A enhancer
• Reinfuse modified blood stem cells to patient
Potential benefits:
• Loss of BCL11A expression in red blood cells causing increased fetal hemoglobin
• Spares BCL11A expression in other blood cells
• Modification would be permanent
• Survival advantage of cells (would outcompete unmodified cells)
• Compared to gene addition, no semi-random insertion of material into the genome, and no need for lifelong expression of foreign sequences
Potential risks:
• Genome modification at sites other than the intended target
• Preparation (“conditioning”) therapy for stem cell transplant (shared risk of both gene addition and genome editing; potentially much less toxic than for “allotransplant” (from related or unrelated donor)
The vision: mimicking common protective genetic variation for therapeutic benefit
![Page 30: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/30.jpg)
Summary
• -thalassemia results from mutations in -globin, a single gene within a large genome
• Gene addition adds a copy of -globin by semi-random integration into the genome– Currently being tested in early-phase clinical trials– Challenges include: durable high-level expression; ensuring other
important genes are not disrupted due to integration
• Genome editing offers the promise of precise and permanent genome modification to mimic protective genetic variation (e.g. at BCL11A) or to repair -globin– Challenges include: effective delivery of genome editing tools to
cells to achieve efficient target disruption/repair; ensuring modification is limited to intended target
![Page 31: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/31.jpg)
Acknowledgments
Boston Children’s
Ellis Neufeld
David Williams
David Nathan
Jennifer Eile
Alan Cantor
Bill Pu
Dana-Farber Cancer Institute
GC Yuan
Luca Pinello
Broad Institute
Feng Zhang
Neville Sanjana
Ophir Shalem
Boston Children’s Hospital
Stuart Orkin
Jian Xu
Vijay Sankaran
Sophia Kamran
Matthew Canver
Carrie Lin
Abhishek Dass
Yuko Fujiwara
Zhen Shao
E. Crew Smith
Cong Peng
Hojun Li
Montreal Heart Institute
Guillaume Lettre
Samuel Lessard
Stanford University
Matthew Porteus
Richard Voit
University of Washington
John Stamatoyannopoulos
Peter Sabo
Jeff Vierstra
![Page 32: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/32.jpg)
•Feasibility
The vision: mimicking common protective genetic variation for therapeutic benefit
ASH 2013 Abstracts #434 and 4213. Slide courtesy of Sangamo BioSciences.
![Page 33: Genome Editing for Thalassemia CAF Patient-Family Conference 21 June 2014 Daniel E. Bauer, MD PhD](https://reader036.vdocument.in/reader036/viewer/2022081603/568146ce550346895db40635/html5/thumbnails/33.jpg)
•Feasibility
The vision: mimicking common protective genetic variation for therapeutic benefit
Tebas et al. NEJM (2014) 370:901.